<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Phendimetrazine</strong></td></tr><tr><th>Accession Number</th><td><strong>DB01579</strong></td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved, illicit</td></tr><tr><th>Description</th><td><p>Phendimetrazine is a weight loss medication. Phendimetrazine is chemically related to amphetamines and is a Schedule <span class="caps">III</span> drug under the Convention on Psychotropic Substances. In the United States, phendimetrazine is a Schedule <span class="caps">III</span> controlled substance under the Uniform Controlled Substances Act of 1970.</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB01579/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB01579/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01579.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01579.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01579.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01579.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01579.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB01579">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Salts</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Adipost</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Bontril</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Melfiat</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Statobex</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/central-nervous-system-stimulants">Central Nervous System Stimulants</a></li>
<li><a href="/mesh/appetite-depressants">Appetite Depressants</a></li></ul></td></tr><tr><th>CAS number</th><td>634-03-7</td></tr><tr><th>Weight</th><td>Average: 191.2695<br>Monoisotopic: 191.131014171</td></tr><tr><th>Chemical Formula</th><td>C<sub>12</sub>H<sub>17</sub>NO</td></tr><tr><th>InChI Key</th><td>MFOCDFTXLCYLKU-UHFFFAOYSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C12H17NO/c1-10-12(14-9-8-13(10)2)11-6-4-3-5-7-11/h3-7,10,12H,8-9H2,1-2H3</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">3,4-dimethyl-2-phenylmorpholine</div></td></tr><tr><th>SMILES</th><td><div class="wrap">CC1C(OCCN1C)C1=CC=CC=C1</div></td></tr><tr><th>Mass Spec</th><td><a href="/system/mass_specs/DB01579.gif?1265922771">show</a>(8.7 KB)</td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Heterocyclic Compounds</td></tr><tr><th>Class</th><td>Oxazinanes</td></tr><tr><th>Subclass</th><td>Morpholines</td></tr><tr><th>Direct parent</th><td>Phenylmorpholines</td></tr><tr><th>Alternative parents</th><td>Benzene and Substituted Derivatives; Tertiary Amines; Dialkyl Ethers; Polyamines</td></tr><tr><th>Substituents</th><td>benzene; tertiary amine; dialkyl ether; polyamine; ether; amine; organonitrogen compound</td></tr><tr><th>Classification description</th><td>This compound belongs to the phenylmorpholines. These are aromatic compounds containing a morpholine ring and a benzene ring linked to each other through a CC or a CN bond.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>Used in the management of exogenous obesity as a short term adjunct (a few weeks) in a regimen of weight reduction based on caloric restriction.</td></tr><tr><th>Pharmacodynamics</th><td>Phendimetrazine is a phenylalkylamine sympathomimetic amine with pharmacological activity similar to the prototype drugs of this class used in obesity, the amphetamines. Actions include central nervous system stimulation and elevation of blood pressure. Tachyphylaxis and tolerance has been demonstrated with all drugs of this class in which these phenomena have been looked for. Drugs of this class used in obesity are commonly known as ''anorectics or anorexigenics." It has not been established, however, that the action of such drugs in treating obesity is primarily one of appetite suppression. Other central nervous system actions or metabolic effects, may be involved.</td></tr><tr><th>Mechanism of action</th><td>Phendimetrazine may act in a similar way to amphetamines in that it activates the alpha-adrenergic system to induce an appetite suppressive and metabolic increase effect. The drug also acts as a norepinephrine-dopamine releasing agent (NDRA). It can bind to and reverse the NET.</td></tr><tr><th>Absorption</th><td>Peak plasma levels occur within 1 to 3 hours. Absorption is usually complete by 4 to 6 hours.</td></tr><tr><th>Volume of distribution</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Protein binding</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Approximately 30% of a given dose of phendimetrazine is metabolized into phenmetrazine, which may account for part of its anorectic effect, and probably also influences abuse potential; individuals who metabolise a greater proportion of phendimetrazine into phenmetrazine are more likely to develop problems with dependence and addiction</p><table class="table-standard table-condensed" id="experimental-properties"><thead><tr><th>Substrate</th><th>Enzymes</th><th colspan="2">Product</th></tr></thead><tbody><tr><td>Phendimetrazine</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><span class="wishart wishart-not-available">Not Available</span></td><td><a href="/metabolites/DBMET00626">Phenmetrazine</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/645">Details</a></td></tr></tbody></table></td></tr><tr><th>Route of elimination</th><td>The major route of elimination is via the kidneys where most of the drug and metabolites are excreted.</td></tr><tr><th>Half life</th><td>19-24 hours</td></tr><tr><th>Clearance</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Toxicity</th><td>Acute overdosage of phendimetrazine may manifest itself by the following signs and symptoms: unusual restlessness, confusion, belligerance, hallucinations, and panic states. Fatigue and depression usually follow the central stimulation. Cardiovascular effects include arrhythmias, hypertension, or hypotension and circulatory collapse. Gastrointestinal symptoms include nausea, vomiting, diarrhea, and abdominal cramps. Poisoning may result in convulsions, coma and death.</td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>0.9969</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              +
        </td>
        <td>0.9846</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              +
        </td>
        <td>0.7977</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Substrate
        </td>
        <td>0.6041</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.6769</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.9583</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Inhibitor
        </td>
        <td>0.643</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.8398</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Substrate</td>
        <td>0.6133</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Substrate</td>
        <td>0.6142</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.7819</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9346</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.6649</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.6534</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8458</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>Low CYP Inhibitory Promiscuity</td>
        <td>0.8231</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.8256
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.9313
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            0.9087
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          2.6514 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.7016
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Non-inhibitor 
        </td>
        <td>
            0.7799
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>Valeant pharmaceuticals international</li>
<li>Numark laboratories inc</li>
<li>Dm graham laboratories inc</li>
<li>Sandoz inc</li>
<li>Shire richwood inc</li>
<li>Mm mast and co</li>
<li>Vitarine pharmaceuticals inc</li>
<li>Solvay pharmaceuticals</li>
<li>Teva pharmaceuticals usa inc</li>
<li>Ferndale laboratories inc</li>
<li>Abc holding corp</li>
<li>Camall co inc</li>
<li>Tg united labs llc</li>
<li>Private formulations inc</li>
<li>Forest pharmaceuticals inc</li>
<li>Actavis totowa llc</li>
<li>Barr laboratories inc</li>
<li>Inwood laboratories inc sub forest laboratories inc</li>
<li>Ivax pharmaceuticals inc</li>
<li>Ivax pharmaceuticals inc sub teva pharmaceuticals usa</li>
<li>Kv pharmaceutical co</li>
<li>Manufacturing chemists inc</li>
<li>Mikart inc</li>
<li>Nexgen pharma inc</li>
<li>Usl pharma inc</li>
<li>Watson laboratories inc</li>
<li>Wyeth ayerst laboratories</li></ul></td></tr><tr><th>Packagers</th><td><ul><li>Apotheca Inc.</li>
<li><a href="http://orders.a-smeds.com">A-S Medication Solutions LLC</a></li>
<li><a href="http://bryantranchprepack.com">Bryant Ranch Prepack</a></li>
<li>C.O. Truxton Inc.</li>
<li><a href="http://www.calvinscottinc.com">Calvin Scott and Co. Inc.</a></li>
<li>D.M. Graham Laboratories Inc.</li>
<li>DispenseXpress Inc.</li>
<li><a href="http://www.drxdispensing.com">Dispensing Solutions</a></li>
<li><a href="http://www.dhscorp.com">Diversified Healthcare Services Inc.</a></li>
<li>Eon Labs</li>
<li><a href="http://www.hhlabs.com">H and H Laboratories</a></li>
<li>Kraft Pharmaceutical Co. Inc.</li>
<li>Macnary Ltd.</li>
<li><a href="http://www.majorpharmaceuticals.com">Major Pharmaceuticals</a></li>
<li><a href="http://www.mckesson.com">Mckesson Corp.</a></li>
<li><a href="http://www.mikart.com">Mikart Inc.</a></li>
<li><a href="http://www.nexgenpharma.com">Nexgen Pharma Inc.</a></li>
<li><a href="http://www.nucarerx.com">Nucare Pharmaceuticals Inc.</a></li>
<li><a href="http://www.numarklabs.com">Numark Laboratories Inc.</a></li>
<li><a href="http://www.palmettopharm.com">Palmetto Pharmaceuticals Inc.</a></li>
<li><a href="http://www.pdrx.com">PD-Rx Pharmaceuticals Inc.</a></li>
<li><a href="http://www.pharmapacllc.com">Pharma Pac LLC</a></li>
<li><a href="http://www.physicianstotalcare.com">Physicians Total Care Inc.</a></li>
<li><a href="http://www.preferredpharmaceuticals.com">Preferred Pharmaceuticals Inc.</a></li>
<li><a href="http://www.prepaksys.com">Prepak Systems Inc.</a></li>
<li>Quality Research Pharmaceutical Inc.</li>
<li><a href="http://www.rebelrx.com">Rebel Distributors Corp.</a></li>
<li><a href="http://www.schering.de">Schering Corp.</a></li>
<li><a href="http://www.southwoodhealthcare.com">Southwood Pharmaceuticals</a></li>
<li><a href="http://www.urlpharma.com">United Research Laboratories Inc.</a></li>
<li><a href="http://www.valeant.com">Valeant Ltd.</a></li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Tablet</td><td>Oral</td><td></td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB00477">Chlorpromazine</a></td><td>Decreased anorexic effect, may increases psychotic symptoms</td></tr><tr><td><a href="/drugs/DB00472">Fluoxetine</a></td><td>Risk of serotoninergic syndrome</td></tr><tr><td><a href="/drugs/DB00623">Fluphenazine</a></td><td>Decreased anorexic effect, may increase psychotic symptoms</td></tr><tr><td><a href="/drugs/DB00176">Fluvoxamine</a></td><td>Risk of serotoninergic syndrome</td></tr><tr><td><a href="/drugs/DB01170">Guanethidine</a></td><td>Phendimetrazine may decrease the effect of guanethidine.</td></tr><tr><td><a href="/drugs/DB01247">Isocarboxazid</a></td><td>Possible hypertensive crisis</td></tr><tr><td><a href="/drugs/DB00933">Mesoridazine</a></td><td>Decreased anorexic effect, may increase psychotic symptoms</td></tr><tr><td><a href="/drugs/DB01403">Methotrimeprazine</a></td><td>Decreased anorexic effect, may increase psychotic symptoms</td></tr><tr><td><a href="/drugs/DB00715">Paroxetine</a></td><td>Risk of serotoninergic syndrome</td></tr><tr><td><a href="/drugs/DB00850">Perphenazine</a></td><td>Decreased anorexic effect, may increase psychotic symptoms</td></tr><tr><td><a href="/drugs/DB00780">Phenelzine</a></td><td>Possible hypertensive crisis</td></tr><tr><td><a href="/drugs/DB00433">Prochlorperazine</a></td><td>Decreased anorexic effect, may increase pyschotic symptoms</td></tr><tr><td><a href="/drugs/DB01069">Promethazine</a></td><td>Decreased anorexic effect, may increase pyschotic symptoms</td></tr><tr><td><a href="/drugs/DB01608">Propericiazine</a></td><td>Decreased anorexic effect, may increase pyschotic symptoms</td></tr><tr><td><a href="/drugs/DB01367">Rasagiline</a></td><td>Possible hypertensive crisis</td></tr><tr><td><a href="/drugs/DB00679">Thioridazine</a></td><td>Decreased anorexic effect, may increase psychotic symptoms</td></tr><tr><td><a href="/drugs/DB00193">Tramadol</a></td><td>Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.</td></tr><tr><td><a href="/drugs/DB00519">Trandolapril</a></td><td>Phendimetrazine may reduce the efficacy of Trandolapril. </td></tr><tr><td><a href="/drugs/DB00752">Tranylcypromine</a></td><td>The MAO inhibitor, Tranylcypromine, may increase the vasopressor effect of the amphetamine, Phendimetrazine. Concomitant therapy should be avoided.</td></tr><tr><td><a href="/drugs/DB00831">Trifluoperazine</a></td><td>Decreased anorexic effect, may increase psychotic symptoms</td></tr><tr><td><a href="/drugs/DB00427">Triprolidine</a></td><td>Triprolidine may reduce the sedative effect of the antihistamine, Phendimetrazine.</td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table>